Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter Business Wire (press release) Approved and investigational therapies in Biogen Idec's MS franchise presented at the conference included BG-12, daclizumab-HYP, anti-LINGO, TYSABRI, AVONEX and FAMPYRA® (prolonged-release fampridine tablets). Third Quarter Events ... |
